Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL
- 1 July 2007
- journal article
- Published by Elsevier in Experimental Cell Research
- Vol. 313 (11) , 2378-2388
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Cutting Edge: TRAIL Deficiency Accelerates Hematological MalignanciesThe Journal of Immunology, 2005
- Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1Cell Death & Differentiation, 2005
- Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis SignalingJournal of Biological Chemistry, 2005
- Targeting death receptors in cancer with Apo2L/TRAILCurrent Opinion in Pharmacology, 2004
- Role of Apo2L/TRAIL and Bcl-2-family Proteins in Apoptosis of Multiple MyelomaLeukemia & Lymphoma, 2003
- Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentJournal of Experimental Medicine, 2002
- TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapyLeukemia, 2001
- Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasiasExpert Opinion on Investigational Drugs, 2001
- TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cellsLeukemia, 1999
- Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy ReceptorsScience, 1997